Table 2 Ranibizumab versus bevacizumab for myopic CNV: BCVA and CFT changes at month 6 and 12 after treatment
Ranibizumab | Bevacizumab | P value* | |
|---|---|---|---|
BCVA changes at month 6 | |||
Gained ≥ 2 Lines | 18/23 (78%) | 27/43 (63%) | 0.24 |
Lost ≤ 2 Lines | 1/23 (4%) | 1/43 (2%) | 0.99 |
BCVA changes at month 12 | |||
Gained ≥ 2 Lines | 17/23 (74%) | 27/43 (63%) | 0.43 |
Lost ≤ 2 Lines | 1/23 (4%) | 2/43 (5%) | 0.99 |
CFT changes at month 6 | |||
Decreased by 10% or more | 13/17 (77%) | 24/32 (75%) | 0.91 |
Equal | 4/17 (23%) | 7/32 (22%) | |
Increased by 10% or more | 0/17 (0%) | 1/32 (3%) | 0.99 |
CFT changes at month 12 | |||
Decreased by 10% or more | 14/17 (82%) | 22/32 (69%) | 0.50 |
Equal | 3/17 (18%) | 8/32 (25%) | |
Increased by 10% or more | 0/17 (0%) | 2/32 (6%) | 0.54 |